;PMID: 2788364
;source_file_1005.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..147] = [t:41..147]
;2)section:[e:151..213] = [t:151..213]
;3)section:[e:217..315] = [t:217..315]
;4)sentence:[e:319..454] = [t:319..454]
;5)sentence:[e:455..617] = [t:455..617]
;6)sentence:[e:618..795] = [t:618..795]
;7)sentence:[e:796..984] = [t:796..984]
;8)sentence:[e:985..1112] = [t:985..1112]
;9)sentence:[e:1113..1316] = [t:1113..1316]
;10)sentence:[e:1317..1364] = [t:1317..1364]
;11)sentence:[e:1365..1507] = [t:1365..1507]
;12)sentence:[e:1508..1649] = [t:1508..1649]
;13)section:[e:1653..1697] = [t:1653..1697]

;section 0 Span:0..35
;Am J Med Sci. 1989 Aug;298(2):83-8.
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..8] Med) (NNP:[9..12] Sci)
        (.:[12..13] .) (CD:[14..18] 1989) (CC:[19..27] Aug;298-LRB-)
        (CD:[27..28] 2) (-RRB-:[28..29] -RRB-) (CD:[29..32] :83) (::[32..33] -)
        (CD:[33..35] 8.)))

;sentence 1 Span:41..147
;19-Hydroxylase inhibition of adrenal mitochondrial P450 11 
;beta/18/19-hydroxylase by a suicide inhibitor.
;[41..55]:substance:"19-Hydroxylase"
;[92..105]...[111..123]:substance:"P450 11  beta"..."-hydroxylase"
;[92..96]...[106..108]...[111..123]:substance:"P450"..."18"..."-hydroxylase"
;[92..96]...[109..123]:substance:"P450"..."19-hydroxylase"
;[137..146]:substance:"inhibitor"
(SENT
  (NP-HLN
    (NP (NN:[41..55] 19-Hydroxylase) (NN:[56..66] inhibition))
    (PP (IN:[67..69] of)
      (NP (JJ:[70..77] adrenal) (JJ:[78..91] mitochondrial) (NN:[92..96] P450)
        (NML
          (NML (CD:[97..99] 11) (SYM:[101..105] beta))
          (SYM:[105..106] /)
          (NML (CD:[106..108] 18))
          (SYM:[108..109] /)
          (NML (CD:[109..111] 19)))
        (HYPH:[111..112] -) (NN:[112..123] hydroxylase)))
    (PP (IN:[124..126] by)
      (NP (DT:[127..128] a) (NN:[129..136] suicide) (NN:[137..146] inhibitor)))
    (.:[146..147] .)))

;section 2 Span:151..213
;Griffing GT, Holbrook M, Melby JC, Alberta J, Orme-Johnson NR.
(SEC
  (FRAG (NNP:[151..159] Griffing) (NNP:[160..162] GT) (,:[162..163] ,)
        (NNP:[164..172] Holbrook) (NNP:[173..175] M,) (NNP:[176..181] Melby)
        (NNP:[182..184] JC) (,:[184..185] ,) (NNP:[186..193] Alberta)
        (NNP:[194..196] J,) (NNP:[197..201] Orme) (::[201..202] -)
        (NNP:[202..209] Johnson) (NNP:[210..212] NR) (.:[212..213] .)))

;section 3 Span:217..315
;Evans Memorial Department of Clinical Research, University Hospital, Boston, 
;Massachusetts 02118.
(SEC
  (FRAG (NNP:[217..222] Evans) (NNP:[223..231] Memorial)
        (NNP:[232..242] Department) (IN:[243..245] of) (NNP:[246..254] Clinical)
        (NNP:[255..263] Research) (NNP:[263..264] ,) (NNP:[265..275] University)
        (NNP:[276..284] Hospital) (,:[284..285] ,) (NNP:[286..292] Boston)
        (,:[292..293] ,) (NNP:[295..308] Massachusetts) (VBD:[309..314] 02118)
        (.:[314..315] .)))

;sentence 4 Span:319..454
;19-Nor-deoxycorticosterone (19-nor-DOC) is a mineralocorticoid that is
;increased  in some forms of experimental and human hypertension.
;[319..345]:substance:"19-Nor-deoxycorticosterone"
;[347..357]:substance:"19-nor-DOC"
;[364..381]:substance:"mineralocorticoid"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[319..345] 19-Nor-deoxycorticosterone))
      (NP (-LRB-:[346..347] -LRB-) (NN:[347..357] 19-nor-DOC)
          (-RRB-:[357..358] -RRB-)))
    (VP (VBZ:[359..361] is)
      (NP-PRD
        (NP (DT:[362..363] a) (NN:[364..381] mineralocorticoid))
        (SBAR
          (WHNP-2 (WDT:[382..386] that))
          (S
            (NP-SBJ-2 (-NONE-:[386..386] *T*))
            (VP (VBZ:[387..389] is)
              (VP (VBN:[390..399] increased)
                (NP-2 (-NONE-:[399..399] *))
                (PP (IN:[401..403] in)
                  (NP
                    (NP (DT:[404..408] some) (NNS:[409..414] forms))
                    (PP (IN:[415..417] of)
                      (NP
                        (NP (JJ:[418..430] experimental)
                          (NML-1 (-NONE-:[430..430] *P*)))
                        (CC:[431..434] and)
                        (NP (JJ:[435..440] human)
                          (NML-1 (NN:[441..453] hypertension)))))))))))))
    (.:[453..454] .)))

;sentence 5 Span:455..617
;The pivotal step in  19-nor-DOC biosynthesis is adrenal P450 19-hydroxylase,
;but this enzyme has not  been clearly distinguished from P450 11
;beta/18-hydroxylase.
;[476..486]:substance:"19-nor-DOC"
;[511..530]:substance:"P450 19-hydroxylase"
;[541..547]:substance:"enzyme"
;[589..601]...[604..616]:substance:"P450 11 beta"..."-hydroxylase"
;[589..593]...[602..616]:substance:"P450"..."18-hydroxylase"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[455..458] The) (JJ:[459..466] pivotal) (NN:[467..471] step))
        (PP (IN:[472..474] in)
          (NP (NN:[476..486] 19-nor-DOC) (NN:[487..499] biosynthesis))))
      (VP (VBZ:[500..502] is)
        (NP-PRD (JJ:[503..510] adrenal)
           (NN:[511..515] P450) (NN:[516..530] 19-hydroxylase))))
    (,:[530..531] ,) (CC:[532..535] but)
    (S
      (NP-SBJ-1 (DT:[536..540] this) (NN:[541..547] enzyme))
      (VP (VBZ:[548..551] has) (RB:[552..555] not)
        (VP (VBN:[557..561] been)
          (ADVP (RB:[562..569] clearly))
          (VP (VBN:[570..583] distinguished)
            (NP-1 (-NONE-:[583..583] *))
            (PP (IN:[584..588] from)
              (NP (NN:[589..593] P450)
                (NML
                  (NML (CD:[594..596] 11) (SYM:[597..601] beta))
                  (SYM:[601..602] /)
                  (NML (CD:[602..604] 18)))
                (HYPH:[604..605] -) (NN:[605..616] hydroxylase)))))))
    (.:[616..617] .)))

;sentence 6 Span:618..795
;This study  attempted to specifically inhibit adrenal 19-hydroxylation of 
;deoxycorticosterone (DOC) using a suicide aromatase inhibitor, 19-acetylenic 
;androstenedione (19-AA).
;[693..712]:substance:"deoxycorticosterone"
;[714..717]:substance:"DOC"
;[735..744]:substance:"aromatase"
;[745..754]:substance:"inhibitor"
;[756..786]:substance:"19-acetylenic  androstenedione"
;[788..793]:substance:"19-AA"
(SENT
  (S
    (NP-SBJ-1 (DT:[618..622] This) (NN:[623..628] study))
    (VP (VBD:[630..639] attempted)
      (S
        (NP-SBJ-1 (-NONE-:[639..639] *))
        (VP (TO:[640..642] to)
          (ADVP (RB:[643..655] specifically))
          (VP (VB:[656..663] inhibit)
            (NP
              (NP (JJ:[664..671] adrenal) (NN:[672..688] 19-hydroxylation))
              (PP (NN:[689..691] of)
                (NP
                  (NP (NN:[693..712] deoxycorticosterone))
                  (NP (-LRB-:[713..714] -LRB-) (NN:[714..717] DOC)
                      (-RRB-:[717..718] -RRB-)))))
            (S-MNR
              (NP-SBJ (-NONE-:[718..718] *))
              (VP (VBG:[719..724] using)
                (NP
                  (NP (DT:[725..726] a) (NN:[727..734] suicide)
                      (NN:[735..744] aromatase) (NN:[745..754] inhibitor))
                  (,:[754..755] ,)
                  (NP
                    (NP (JJ:[756..769] 19-acetylenic)
                        (NN:[771..786] androstenedione))
                    (NP (-LRB-:[787..788] -LRB-) (NN:[788..793] 19-AA)
                        (-RRB-:[793..794] -RRB-))))))))))
    (.:[794..795] .)))

;sentence 7 Span:796..984
;Purified bovine P450 11 beta/18/19-hydroxylase was  incubated with excess
;substrate DOC, adrenodoxin, and adrenodoxin reductase in  the presence of
;increasing doses of the inhibitor, 19AA.
;[812..824]...[830..842]:substance:"P450 11 beta"..."-hydroxylase"
;[812..816]...[828..842]:substance:"P450"..."19-hydroxylase"
;[812..816]...[825..827]...[830..842]:substance:"P450"..."18"..."-hydroxylase"
;[870..879]:substance:"substrate"
;[880..883]:substance:"DOC"
;[885..896]:substance:"adrenodoxin"
;[902..923]:substance:"adrenodoxin reductase"
;[968..977]:substance:"inhibitor"
;[979..983]:substance:"19AA"
(SENT
  (S
    (NP-SBJ-1 (VBN:[796..804] Purified) (JJ:[805..811] bovine)
              (NN:[812..816] P450)
      (NML
        (NML (CD:[817..819] 11) (SYM:[820..824] beta))
        (SYM:[824..825] /)
        (NML (CD:[825..827] 18))
        (SYM:[827..828] /)
        (NML (CD:[828..830] 19)))
      (HYPH:[830..831] -) (NN:[831..842] hydroxylase))
    (VP (VBD:[843..846] was)
      (VP (VBN:[848..857] incubated)
        (NP-1 (-NONE-:[857..857] *))
        (PP-MNR (IN:[858..862] with)
          (NP
            (NP (NN:[863..869] excess) (NN:[870..879] substrate)
                (NN:[880..883] DOC))
            (,:[883..884] ,)
            (NP (NN:[885..896] adrenodoxin))
            (,:[896..897] ,) (CC:[898..901] and)
            (NP (NN:[902..913] adrenodoxin) (NN:[914..923] reductase))))
        (PP (IN:[924..926] in)
          (NP
            (NP (DT:[928..931] the) (NN:[932..940] presence))
            (PP (IN:[941..943] of)
              (NP
                (NP (VBG:[944..954] increasing) (NN:[955..960] doses))
                (PP (IN:[961..963] of)
                  (NP
                    (NP (DT:[964..967] the) (NN:[968..977] inhibitor))
                    (,:[977..978] ,)
                    (NP (NN:[979..983] 19AA))))))))))
    (.:[983..984] .)))

;sentence 8 Span:985..1112
;11 beta-, 18-, and  19-hydroxylation were measured by quantification of
;corticosterone, 18-OH-DOC,  and 19-OH-DOC respectively.
;[1057..1071]:substance:"corticosterone"
;[1073..1082]:substance:"18-OH-DOC"
;[1089..1098]:substance:"19-OH-DOC"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NML (CD:[985..987] 11) (SYM:[988..992] beta))
        (HYPH:[992..993] -)
        (NML-2 (-NONE-:[993..993] *P*)))
      (,:[993..994] ,)
      (NP (CD:[995..997] 18) (HYPH:[997..998] -)
        (NML-2 (-NONE-:[998..998] *P*)))
      (,:[998..999] ,) (CC:[1000..1003] and)
      (NP (CD:[1005..1007] 19) (HYPH:[1007..1008] -)
        (NML-2 (NN:[1008..1021] hydroxylation))))
    (VP (VBD:[1022..1026] were)
      (VP (VBN:[1027..1035] measured)
        (NP-1 (-NONE-:[1035..1035] *))
        (PP-MNR (IN:[1036..1038] by)
          (NP
            (NP (NN:[1039..1053] quantification))
            (PP (IN:[1054..1056] of)
              (NP (NN:[1057..1071] corticosterone) (,:[1071..1072] ,)
                  (NN:[1073..1082] 18-OH-DOC) (,:[1082..1083] ,)
                  (CC:[1085..1088] and) (NN:[1089..1098] 19-OH-DOC)))))
        (ADVP (RB:[1099..1111] respectively))))
    (.:[1111..1112] .)))

;sentence 9 Span:1113..1316
;Measurements of these products demonstrated that 11  beta- and
;18-hydroxylation was not inhibited whereas 19-hydroxylation was  inhibited as
;manifested by decreased 19-OH-DOC formation (p less than .05).
;[1278..1287]:substance:"19-OH-DOC"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1113..1125] Measurements))
      (PP (IN:[1126..1128] of)
        (NP (DT:[1129..1134] these) (NNS:[1135..1143] products))))
    (VP (VBD:[1144..1156] demonstrated)
      (SBAR (IN:[1157..1161] that)
        (S
          (NP-SBJ-3
            (NP
              (NML (CD:[1162..1164] 11) (SYM:[1166..1170] beta))
              (HYPH:[1170..1171] -)
              (NML-2 (-NONE-:[1171..1171] *P*)))
            (CC:[1172..1175] and)
            (NP (CD:[1176..1178] 18) (HYPH:[1178..1179] -)
              (NML-2 (NN:[1179..1192] hydroxylation))))
          (VP (VBD:[1193..1196] was) (RB:[1197..1200] not)
            (VP (VBN:[1201..1210] inhibited)
              (NP-3 (-NONE-:[1210..1210] *))
              (SBAR-ADV (IN:[1211..1218] whereas)
                (S
                  (NP-SBJ-1 (NN:[1219..1235] 19-hydroxylation))
                  (VP (VBD:[1236..1239] was)
                    (VP (VBN:[1241..1250] inhibited)
                      (NP-1 (-NONE-:[1250..1250] *))
                      (SBAR-ADV (IN:[1251..1253] as)
                        (S
                          (NP-SBJ (-NONE-:[1253..1253] *))
                          (VP (VBN:[1254..1264] manifested)
                            (PP (IN:[1265..1267] by)
                              (NP-LGS (VBN:[1268..1277] decreased)
                                      (NN:[1278..1287] 19-OH-DOC)
                                      (NN:[1288..1297] formation))))))))))
              (PRN (-LRB-:[1298..1299] -LRB-)
                (S
                  (NP-SBJ (NN:[1299..1300] p))
                  (ADJP-PRD
                    (ADJP (JJR:[1301..1305] less))
                    (PP (IN:[1306..1310] than)
                      (NP (CD:[1311..1314] .05)))))
                (-RRB-:[1314..1315] -RRB-)))))))
    (.:[1315..1316] .)))

;sentence 10 Span:1317..1364
;The  IC50 of 19-AA was approximately 10(-12) M.
;[1322..1326]:quantitative-name:"IC50"
;[1330..1335]:substance:"19-AA"
;[1354..1361]:quantitative-value:"10(-12)"
;[1362..1363]:quantitative-units:"M"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1317..1320] The) (NN:[1322..1326] IC50))
      (PP (IN:[1327..1329] of)
        (NP (NN:[1330..1335] 19-AA))))
    (VP (VBD:[1336..1339] was)
      (NP-PRD
        (QP (RB:[1340..1353] approximately) (CD:[1354..1361] 10-LRB--12-RRB-))
        (NN:[1362..1363] M)))
    (.:[1363..1364] .)))

;sentence 11 Span:1365..1507
;The specific inhibition of  19-hydroxylation suggests that the 19-hydroxylase
;may be an enzyme distinct from  the P450 11 beta/18-hydroxylase.
;[1428..1442]:substance:"19-hydroxylase"
;[1453..1459]:substance:"enzyme"
;[1479..1491]...[1494..1506]:substance:"P450 11 beta"..."-hydroxylase"
;[1479..1483]...[1492..1506]:substance:"P450"..."18-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1365..1368] The) (JJ:[1369..1377] specific)
          (NN:[1378..1388] inhibition))
      (PP (IN:[1389..1391] of)
        (NP (NN:[1393..1409] 19-hydroxylation))))
    (VP (VBZ:[1410..1418] suggests)
      (SBAR (IN:[1419..1423] that)
        (S
          (NP-SBJ (DT:[1424..1427] the) (NN:[1428..1442] 19-hydroxylase))
          (VP (MD:[1443..1446] may)
            (VP (VB:[1447..1449] be)
              (NP-PRD
                (NP (DT:[1450..1452] an) (NN:[1453..1459] enzyme))
                (ADJP (JJ:[1460..1468] distinct)
                  (PP (IN:[1469..1473] from)
                    (NP (DT:[1475..1478] the) (NN:[1479..1483] P450)
                      (NML
                        (NML (CD:[1484..1486] 11) (SYM:[1487..1491] beta))
                        (SYM:[1491..1492] /)
                        (NML (CD:[1492..1494] 18)))
                      (HYPH:[1494..1495] -) (NN:[1495..1506] hydroxylase))))))))))
    (.:[1506..1507] .)))

;sentence 12 Span:1508..1649
;This further suggests that 19-nor-DOC  biosynthesis may be under independent
;regulation and may be amendable to  specific in vivo inhibition.
;[1535..1545]:substance:"19-nor-DOC"
(SENT
  (S
    (NP-SBJ (DT:[1508..1512] This) (RBR:[1513..1520] further))
    (VP (VBZ:[1521..1529] suggests)
      (SBAR (IN:[1530..1534] that)
        (S
          (NP-SBJ (NN:[1535..1545] 19-nor-DOC) (NN:[1547..1559] biosynthesis))
          (VP (MD:[1560..1563] may)
            (VP (VB:[1564..1566] be)
              (PP-PRD (IN:[1567..1572] under)
                (NP (JJ:[1573..1584] independent) (NN:[1585..1595] regulation))))
            (CC:[1596..1599] and)
            (VP (MD:[1600..1603] may)
              (VP (VB:[1604..1606] be)
                (ADJP-PRD (JJ:[1607..1616] amendable)
                  (PP (TO:[1617..1619] to)
                    (NP (JJ:[1621..1629] specific)
                      (ADJP (FW:[1630..1632] in) (FW:[1633..1637] vivo))
                      (NN:[1638..1648] inhibition))))))))))
    (.:[1648..1649] .)))

;section 13 Span:1653..1697
;PMID: 2788364 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1653..1657] PMID) (::[1657..1658] :) (CD:[1659..1666] 2788364)
        (NN:[1667..1668] -LSB-) (NNP:[1668..1674] PubMed) (::[1675..1676] -)
        (NN:[1677..1684] indexed) (IN:[1685..1688] for)
        (NNP:[1689..1697] MEDLINE-RSB-)))
